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ABSTRACT 
 
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are the most common neurodegenerative diseases and there  
is increasing evidence that they share common physiological and pathological links. Here we have conducted the 
largest network analysis of PD and AD based on their gene expressions in blood to date. We identified modules that 
were not preserved between disease and healthy control (HC) networks, and important hub genes and transcription 
factors (TFs) in these modules. We highlighted that the PD module not preserved in HCs was associated with insulin 
resistance, and HDAC6 was identified as a hub gene in this module which may have the role of influencing tau  
phosphorylation and autophagic flux in neurodegenerative disease. The AD module associated with regulation of 
lipolysis in adipocytes and neuroactive ligand-receptor interaction was not preserved in healthy and mild cognitive 
impairment networks and the key hubs TRPC5 and BRAP identified as potential targets for therapeutic treatments of 
AD. Our study demonstrated that PD and AD share common disrupted genetics and identified novel pathways, hub 
genes and TFs that may be new areas for mechanistic study and important targets in both diseases. 
 
 
INTRODUCTION 
 
Alzheimer’s disease (AD) is the most common 
neurodegenerative disease (ND) and dementia, accounting 
for 60-80% of dementia cases. AD is characterized 
pathologically by accumulation of extracellular amyloid- 
β1 (Aβ) and deposits of intracellular tau neurofibrillary 
tangles [1]. In the US, the number of people living with 
AD is projected to increase from 5.5 million in 2018 to 
13.8 million by 2050 [2]. Gradual progressive memory 
loss is the most common clinical symptom of AD, which 
eventually affects other cognitive functions such as 
communication and movement. There are currently many 
promising advances in the understanding of  AD, 
including discovery of novel biomarkers [3, 4] and 
analysis of underlying biological mechanisms [5]. 
 
Parkinson’s disease (PD) is the second most prevalent ND 
affecting approximately 145,000 people in the UK [6], and 
PD patient numbers are predicted to increase by 87.6% 
between 2015 and 2065 [6]. In the US, the number of PD 
 
cases are predicted to increase from 680,000 to 1,238,000 
by 2030 [7]. The accumulation of α-synuclein in neurons 
in the form of Lewy bodies is the main neuropathologic 
hallmark of PD [8]. Primarily, PD affects the motor 
systems of the central nervous system (CNS) as a result of 
the death of dopamine generating cells in the midbrain 
substantia nigra (SN) [8]. 
 
There is growing evidence that AD and PD share many 
common characteristics [9]. Around 80% of PD patients 
will develop dementia, with an average time of onset 10 
years from PD diagnosis [10]. We have recently shown 
that PD and AD share significant common differentially 
expressed genes (DEGs), disturbed pathways including  
the sirtuin signaling pathway, and identified REST as an 
important upstream regulator in both diseases [11]. AD 
and PD are both age-related diseases that have hallmarks 
of protein aggregation. In fact over 60% of AD cases are 
accompanied by the formation of Lewy bodies and α- 
synuclein is found as a non-amyloid component within 
AD amyloid plaques [12]. In addition, there are certain 
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genetic variants that increase the risk of both AD and PD, 
for example the strong risk factor for AD, APOE4, has 
been shown to be related to cognitive decline in PD [13]. 
 
Gene co-expression relationships contain a wealth of 
information that univariate methods like differential 
expression analysis cannot detect [14]. Weighted gene 
co-expression network analysis (WGCNA)  is  a 
popular tool used in systems biology to construct co- 
expression gene networks which can detect gene 
modules as well as identify key genes and hubs within 
these modules [15]. WGCNA has been used to find 
strong evidence for mitochondrial dysfunction and 
chronic low grade innate immune response  in  AD  
[16]. In addition, Chatterjee et al. [17] identified 11  
hub genes by using WGCNA in frontal cortex and SN 
brain samples of PD patients. 
 
To date there have been no studies investigating PD and 
AD using gene expression network simultaneously to 
reveal potential shared biological process and pathology. 
In this study we analyzed gene co-expression networks 
based on PD and AD blood microarray data and identified 
common genetic networks between both diseases. See our 
analysis workflow illustrated in Figure 1. Compared to 
brain tissues, blood tissue is easier to access from patients 
with ND, and publicly available AD and PD blood 
datasets have a large enough sample size to construct 
reliable and robust networks. Our network analysis 
expands on standard WGCNA and hub detection  
approach which can robustly find key processes and genes 
that are associated with both PD and AD. 
 
RESULTS 
 
Gene co-expression network construction 
 
After quality control, we obtained 19176 genes in the 
PD dataset which included 204 PD and 230 healthy 
control (HC) samples, meanwhile 13661 genes were 
 
 
 
 
 
Figure 1. Workflow of our analysis. Filtered and normalized microarray data were separated into five datasets: AD disease (ADAD), 
healthy control (ADHC) and MCI (ADMCI) data from the AD dataset, and the PD disease (PDPD) and healthy control (PDHC) data from the PD 
dataset. On each dataset gene co-expression networks analysis was performed using the WGCNA R package [15]. An additional k-means 
correction step to reduce number of misplaced genes [70] was then performed and module preservation between cohorts within AD and PD 
was found using NetRep (v.1.2.1) [18]. The pathways associated with non-preserved modules were then found using the Enrichr web tool 
[19,20] and hub genes and transcription factors in these non-preserved modules identified. The SCAN (single nucleotide polymorphism (SNP) 
and Copy number ANnotation) database) database [25] was used to find SNPs associated with the genes in each non-preserved module and 
these SNPs used to search the MiRSNP database to find the SNPs at 3’ UTR of disease associated miRNAs. 
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obtained in the AD dataset which included 245 AD, 142 
mild cognitive impairment (MCI) and 182 HC samples. 
We applied WGCNA [15] to build our networks and 
selected the soft threshold power to define the  
adjacency matrix of each dataset based on approximate 
scale-free topology R2 of 0.85 (Figure 2). In this 
method, highly correlated nodes are placed into a single 
module or cluster which are thought to be regulated by 
similar transcription factors (TFs) and represent certain 
biological processes. These networks were constructed 
for the AD disease (ADAD), healthy control (ADHC) 
and MCI (ADMCI) data from the AD dataset, and the 
PD disease (PDPD) and healthy control (PDHC) data 
from the PD dataset separately. We discovered 27, 54, 
29, 32 and 58 modules in PDPD, PDHC, ADAD, 
ADMCI, ADHC networks respectively. 
 
PD blood and brain DEG overlap 
 
We identified 360 DEGs in the PD blood dataset 
(nominal Pvalue < 0.01, see Supplementary Table 2) 
and compared these DEGs to the DEGs identified in our 
recent meta-analysis study about PD in substantia nigra 
region [11]. An overlap of 21 genes were found 
including LRRN3, BASP1 and TPM3. However, a Fisher 
Exact test was not significant for the overlap showing 
that this was likely by chance (OR = 1.08, 95% CI 
0.65~1.72, Pvalue = 0.72, Fisher Exact test). 
 
 
 
 
 
Figure 2. Scale free network topology (signed R2) for different soft-thresholding powers of data. A soft thresholding power that 
achieved a scale-free topology of R2 of 0.85 was chosen to define approximate scale-free topology. We found that the (A) ADHC data 
achieved approximate scale-free topology at a soft thresholding power of 6 and the (B) ADMCI and (C) ADAD data at a soft thresholding 
power of 4. The (D) PDHC data reached approximate scale-free topology at a soft thresholding power of 10 and (E) PDPD data at a soft 
thresholding power of 13. 
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Identification of non-preserved modules 
 
In our network analysis, if the relationships and 
correlation structure between nodes composing each 
module were not replicated, then they were considered 
non-preserved. In the case of healthy and disease 
networks, non-preserved modules suggested the 
expression pattern and regulation of the genes in these 
modules vary between disease and healthy conditions. 
On the other hand, modules preserved between disease 
and healthy networks represented processes that are not 
affected by disease status. Here we focused on non- 
preserved modules which may help to reveal the disease 
mechanism. The R package NetRep (v1.2.1) was used 
to identify these non-preserved modules [18]. 
 
Table 1 shows the non-preserved modules between PDHC 
and PDPD networks and the biological processes 
associated with these modules. Three of the 54 modules in 
the PDPD network were not preserved in PDHC network, 
and one of those 27 PDHC modules was not preserved in 
the PDPD network. The Gene Ontology (GO) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) terms that 
were significantly enriched within non-preserved modules 
(Pvalue < 0.01) were found using the Enrichr web tool 
[19, 20]. The PDPD salmon module was found to be 
associated with insulin signaling (KEGG pathway, Pvalue 
= 0.0030, 7/108 overlap). The PDPD darkseagreen4 
module was found to be associated with antigen  
processing and presentation (KEGG pathway, Pvalue = 
5.38E-16, overlap = 14/77) and natural killer cell  
mediated cytotoxicity (KEGG pathway, Pvalue = 2.94E- 
15, overlap = 10/41). 
 
Table 2 shows the non-preserved modules between the 
ADHC, ADMCI and ADAD networks. Of the 29 
ADAD modules, one was not preserved in both ADHC 
and ADMCI networks. In addition, one of the 32 
ADMCI modules was not preserved in ADAD and 
ADHC networks. Moreover, three of the 58 ADHC 
modules were not preserved in both ADAD and 
ADMCI networks and one non-preserved in ADMCI 
networks. The ADAD blue module was not preserved in 
ADHC and ADMCI networks and was associated with 
regulation of lipolysis in adipocytes (KEGG pathway, 
Pvalue = 6.24E-4, overlap = 10/55) and neuroactive 
ligand-receptor interaction (KEGG pathway, Pvalue = 
0.005070, overlap = 30/338). The ADHC 
darkolivegreen module was associated with sensory 
perception (GO biological process, Pvalue = 1.83E-4, 
overlap = 8/55). 
 
Identifying hub genes 
 
Hubs are genes that are highly interconnected or 
important within a module and likely have functional 
significance [21]. Hubs have a role in maintaining the 
structure of the gene network of the module and the 
biological processes associated with the module. In our 
study, hub genes were identified using five approaches: 
Betweenness centrality (BC), PageRank, module 
membership (MM), closeness centrality and Kleinberg’s 
centrality. Any gene with a Pvalue < 0.01 in any hub 
detection method was considered as a significant hub 
gene. Using multiple methods for identifying hubs 
allowed for hub identification that may otherwise have 
been missed by use of just one method. To demonstrate 
hub score distribution, Supplementary Figure 2A shows 
an example of betweenness hub score distribution 
across all genes in the PDPD darkseagreen4 module 
which was non-preserved in PDHC network and the 
(Supplementary Figure 2B) distribution of the 
significant GINS2 (Pvalue = 0.005) BC scores across 
the 1000 iterations of the hub permutation test. 
 
We identified 34 hubs in modules not preserved 
between the PDPD and PDHC networks 
(Supplementary Table 3) and 92 hubs in the non- 
preserved modules between ADAD, ADMCI and 
ADHC networks (Supplementary Table 4). It was 
expected that larger modules may have more hubs than 
smaller ones, for example the PDHC purple module 
contained 606 genes, of which 17 were found to be hubs 
(e.g. FAM110C, PAK4, NEB), and the smaller salmon 
PDPD module contained 351 genes, of which only 10 
were hubs (e.g. HDAC6, TYSND1). The PD salmon 
module was associated with insulin resistance and was 
not preserved in PDHC network shown in Figure 3A, 
where hub genes are highlighted. Interestingly, it 
includes HDAC6 which has been shown to influence tau 
phosphorylation and autophagic flux in AD [22]. The 
blue AD module which was associated with regulation 
of lipolysis in adipocytes and neuroactive ligand- 
receptor interaction and was not preserved in ADMCI 
and ADHC networks (Figure 3B) which included 
TRPC5 and BRAP as hub genes. Networks were 
visualized in Gephi [23]. 
 
Identifying transcription factors (TFs) 
 
Genes that are clustered together by WGNCA likely are 
regulated in a similar way, thus we intended to identify 
which TFs potentially regulate the gene expression of 
each module. The TFs that potentially regulate each 
non-preserved module (Pvalue <0.01) were identified 
by using Encyclopedia of DNA Elements (ENCODE) 
and chromatin immunoprecipitation (ChIP) Enrichment 
Analysis (ChEA) consensus TFs from ChIP-X by using 
the Enrichr web tool [19,20]. We found a total of four 
TFs that regulated at least one of the three PDPD 
modules, including FOXM1 which regulated 6 genes in 
the salmon modules (Pvalue = 0.0066) and 9 in the 
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Table 1. List of non-preserved modules found between PD and healthy controls (HC). 
 
Module colour Pvalue of NetRep Processes associated with module found using Enrichr 
No. genes in 
module 
PD modules not preserved in HC 
 
Darkseagreen4 
 
9.99E-5 
Antigen processing and presentation, Natural killer cell 
mediated cytotoxicity, cellular defense response, regulation of 
immune response 
 
150 
Navajowhite2 9.99E-5 cellular response to misfolded protein 150 
Salmon 9.99E-5 Insulin resistance, regulation of protein homooligomerization 351 
HC modules not preserved in PD 
Purple 9.99E-5 
Antigen processing and presentation, VEGF signaling 
pathway, regulation of intracellular transport 
606 
 
 
Table 2. List of non-preserved modules found between AD, MCI and healthy controls (HC). 
 
Module colour Pvalue of NetRep Processes associated with module found using Enrichr 
No. genes in 
module 
AD modules not preserved in HC 
 
Blue 
 
9.99E-5 
Regulation of lipolysis in adipocytes, Neuroactive ligand- 
receptor interaction, detection of chemical stimulus involved 
in sensory perception of smell, extracellular matrix 
organization 
 
1076 
AD modules not preserved in MCI 
 
Blue 
 
9.99E-5 
Regulation of lipolysis in adipocytes, Neuroactive ligand- 
receptor interaction, detection of chemical stimulus involved 
in sensory perception of smell, extracellular matrix 
organization 
 
1076 
MCI modules not preserved in AD 
Sienna3 8.59E-3 
Regulation of lipolysis in adipocytes, axonal fasciculation, 
hippo signaling 
770 
MCI modules not preserved in HC 
Sienna3 9.99E-5 
Regulation of lipolysis in adipocytes, axonal fasciculation, 
hippo signaling 
770 
HC modules not preserved in AD 
Darkolivegreen 9.99E-5 
sensory perception, regulation of potassium ion 
transmembrane transport 
584 
Darkorange2 0.011 Peroxisome, amide transport 248 
Skyblue 0.015 establishment of epithelial cell polarity 187 
HC modules not preserved in MCI 
Darkolivegreen 9.99E-5 
sensory perception, regulation of potassium ion 
transmembrane transport 
584 
Red 9.99E-5 
Regulation of lipolysis in adipocytes, bicellular tight junction 
assembly 
704 
Darkorange2 2.99E-4 Peroxisome, amide transport 248 
Skyblue 0.022 establishment of epithelial cell polarity 187 
 
 
darkseagreen4 module (Pvalue = 4.00E-08). Within one 
PDHC module, there were a total of six TFs, including 
CREB1 which regulated 64 genes in the purple module 
(Pvalue = 0.001402). Supplementary Table 5 shows the 
significant TFs found in modules that were not 
preserved between PD and HC networks. 
We found two TFs (SUZ12, EZH2) regulating non- 
preserved ADAD modules, and one TF (SUZ12) 
regulating 115 genes in the ADMCI sienna3 module 
(Pvalue = 8.24E-10). We also identified 18 TFs that 
regulated at least one of four non-preserved ADHC 
modules. This included REST which regulated 20 genes 
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in  the  darkolivegreen  (Pvalue  =  0.0092)  and  SUZ12 
which regulated 68 genes in the darkolivegreen  (Pvalue 
= 0.0039) and 107 genes in the red module (Pvalue = 
1.21E-09). In addition, CREB1 regulated 29 genes in  
the ADHC darkorange2 module (Pvalue = 0.007005). 
Supplementary Table 6 shows the same for  modules 
that were not preserved between ADAD, ADMCI and 
ADHC. 
 
Single nucleotide polymorphism (SNP) analysis of 
significant WGCNA modules 
 
As non-preserved modules contain genes which play a 
role in processes that were associated with AD or PD, 
they may have been more likely to contain disease 
associated variants than preserved modules. We 
searched each non-preserved PD module for known 
Genome Wide Association Studies (GWAS) genes 
associated with PD [24]. There are 69 known GWAS 
genes, of which four (TMEM163, TLR9, ITIH4, 
TUBG2) were in the salmon module and two 
(TMEM175, STAB1) were in the navajowhite2 module. 
We observed a significant enrichment of GWAS genes 
within modules that were not preserved compared to 
preserved networks (OR = 2.96, 95% CI 1.04~6.88, 
Pvalue = 0.02, Fisher Exact test). Furthermore, the non- 
preserved PDHC purple network contained five GWAS 
gene (KAT8, BIN3, TLR9, ITIH4, TUBG2), however the 
non-preserved HC modules were not more likely to 
contain GWAS genes (OR = 2.61, 95% CI 0.08 ~ 6.47, 
Pvalue = 0.052, Fisher Exact test). We did the same 
analysis for the non-preserved AD modules, however, 
no AD associated GWAS genes were found within any 
non-preserved modules. 
 
In addition to searching for known GWAS genes in 
non-preserved modules, we used the SCAN (SNP and 
Copy number ANnotation) database (http://www. 
scandb.org/) [25] to identify SNPs corresponding to the 
genes in each non-preserved module. These SNPs were 
used to search the MirSNP [26] database to identify 
SNPs associated with known PD or AD microRNAs 
(miRNAs) dependent on the dataset of the module. We 
identified 29 SNPs associated with 9 PD related 
miRNAs across all non-preserved modules in the PD 
dataset (Supplementary Table 7), and 27 SNPs 
associated with 8 AD related miRNAs across all non- 
preserved modules in the AD dataset (Supplementary 
Table 8). 
 
Comparison of AD and PD results 
 
There is increasing evidence that PD and AD share 
several common characteristics [9], thus  we 
investigated the shared processes associated with non- 
preserved modules in both the AD and PD dataset to see 
which were important in both diseases. The biological 
processes found to be associated with significant 
modules in AD and PD were compared to see which 
were important in both diseases. Unfortunately, we did 
 
 
 
 
 
Figure 3. Network visualization of PD and AD modules. (A) Visualization of WGCNA network connections of the PDPD salmon network 
module found to be associated with insulin resistance and not preserved in the PDHC network. It shows network connections whose 
adjacency is above 0.2, including all 351 nodes and 595 of 61776 edges. (B) Visualization of WGCNA network connections of the ADAD blue 
module found to be associated with regulation of lipolysis in adipocytes and neuroactive ligand-receptor interaction and not preserved in 
ADHC and ADMCI networks. It shows network connections whose adjacency is above 0.55, including all 1076 nodes and 1458 of 1157776 
edges. Hub genes are in the center of the network and are labelled with names. Networks visualized in Gephi [23]. 
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not find any significant modules that were common 
between these two. However, we identifed some 
similarities between AD and PD. The PDHC purple 
module and the ADHC darkorange2 module had four 
significant TFs which regulate both modules (SIX5, 
CREB1, NFYB, PBX3). Of those 29 PD SNPs and 27 
AD SNPs we have identified, 12 were common between 
the two. The genes associated with these SNPs were: 
EPB41L5, CYP26B1, IQCB1, DCP1A, CLGN, TDRD6, 
PSORS1C1,    PARP12,    WISP1,    PIK3C2A,   CLMN, 
DHX33 which are highlighted in Supplementary Tables 
7 and 8. 
 
Data accession 
 
The hub scores for each gene in PD modules not 
preserved in HC networks can be accessed and 
downloaded from https://jack-kelly.shinyapps.io/pdpd_ 
hubs/. The same information for HC modules not 
preserved in PD networks can be found at https://jack- 
kelly.shinyapps.io/pdhc_hubs/. 
 
The hub scores for each gene in the AD modules not 
preserved in HC or MCI networks can be found at 
https://jack-kelly.shinyapps.io/adad_hubs/. The same 
for MCI modules not preserved in HC or AD networks 
can be found at https://jack-kelly.shinyapps.io/admci_ 
hubs/ and for HC modules not preserved in MCI or AD 
networks at https://jack-kelly.shinyapps.io/adhc_hubs/. 
 
DISCUSSION 
 
In this study, by using gene co-expression network 
analysis we identified many important biological 
processes and key genes in PD and AD blood samples, 
and the common results between them. To our 
knowledge this is the largest network analysis of AD 
and PD blood to date. We found insulin resistance to be 
associated with PD and HDAC6 may play an important 
role in this process. We highlight the overlap in disease 
miRNA associated SNPs that are shared between PD 
and AD, suggesting similarities in genetic risk factors 
between the diseases. Our approach used blood data as 
the available blood datasets have a large enough sample 
size to construct robust and reliable networks and blood 
samples are easily accessible in neurodegenerative 
disease patients. We previously found that DEGs in AD 
blood were more likely to be DEGs in AD brain tissue 
[27]. However, in this study, we found that DEGs in 
blood were not more likely to be DEGs in brain tissue 
for PD, nevertheless it has been shown that changes in 
blood gene expression did reflect changes in PD [28]. 
 
The PD network module associated with insulin 
resistance is not preserved in HCs. Insulin resistance is 
increasingly being shown to be important in PD as a 
potential therapeutic target [29] and has a high 
prevalence in non-diabetic PD patients [30], 
additionally insulin receptor signaling pathways are 
disturbed in PD [11]. Within this module we identified 
HDAC6 as a hub gene which promotes the formation of 
inclusions from α-synuclein toxic oligomers [31]. 
HDAC6 can promote insulin resistance by deacetylating 
phosphatase and tensin homolog (PTEN) in ovarian 
OVCAR-3 cells [32], and PTEN has in turn been shown 
to be involved in the pathophysiology of PD [33]. 
HDAC6 has a role in influencing tau phosphorylation 
and autophagic flux in neurodegenerative disease [22]. 
In addition, insulin signaling promotes the DNA- 
binding activity of FOXM1, identified as a significant 
TF in the insulin resistance module, which regulates 
pathways to promote adaptive pancreatic β cell 
proliferation [34], but its role in ND is not clear. 
 
The PD module associated with cellular response to 
misfolded proteins was also not preserved in HC 
networks. PD is characterized by accumulation of 
misfolded α-synuclein and a failure of the proteasome to 
degrade these and other large protein aggregates [35]. 
The hub gene SNRNP70 has been shown to be 
differentially expressed in PD blood previously [36]. 
Additionally, SNRNP70 encodes the small nuclear 
ribonucleoprotein snRNP70 which co-localizes with tau 
in AD [37], and as tau aggregation is shown in ~50% of 
PD cases snRNP70 may colocalize in PD cases [38]. 
We also identified MIR142, which encodes miRNA- 
142, as a hub. miRNA-142 has been identified as an 
important miRNA in PD, regulating GNAQ, TMTC2, 
BEND2, and KYNU [39]. 
 
The AD module associated with regulation of lipolysis 
in adipocytes and neuroactive ligand-receptor 
interaction was not preserved in both MCI and HC 
networks. Aβ, a key molecule in AD brain pathology, 
can induce lipolysis within human adipose tissue [40]. 
In addition, lipolysis is promoted by insulin resistance 
and in turn lipolysis generates ceramides further 
impairing insulin signaling, which is becoming 
increasingly more important in AD [41]. We identified 
TRPC5 as a hub in this module, which along with other 
transient receptor potential canonical (TRPC) proteins 
assembles to form non-selective Ca2+-permeable 
channels. Another hub, BRAP, has a polymorphism 
associated with obesity and other metabolic  traits, 
which can play a role in effecting insulin signaling and 
aging [42]. Interestingly, a module in the HC network 
that was not preserved in AD and MCI networks was 
also associated with regulation of lipolysis in 
adipocytes. This suggests that these processes are 
occurring in both healthy and AD conditions, however 
the enrichment pathways are different between the two. 
As no hubs are shared between the regulation of 
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lipolysis in adipocytes modules in healthy and AD 
networks they are likely regulated differently. 
 
The module associated with sensory perception in the 
HC network was not preserved in AD and MCI 
networks. Sensory dysfunction may precede the 
cognitive symptoms of AD [43], particularly olfactory 
impairment [44]. OR5AS1 was identified as a hub gene 
within the module which encodes a member of the 
olfactory receptor family and plays a role in triggering 
response to smells [45]. The TF REST was identified as 
a regulator of the module and has been shown to 
regulate olfactory systems [46]. We have identified 
REST to be an important upstream TF for DEGs 
identified in both AD and PD previously, and as an 
important potential therapeutic target [11]. Future work 
to validate our identified hubs and TFs in both AD and 
PD disease models would further elucidate their 
potential as targets for disease treatment. 
 
Although we did not identify any common non- 
preserved modules in the AD and PD cohorts, there 
were other similarities shared in the results. Four TFs 
were shared between the PDHC purple and the ADHC 
darkorange2 module (CREB1, NFYB, PBX3, SIX5). 
These two modules were associated with different 
transport pathways in HCs which were not preserved in 
the disease networks, suggesting that the roles of these 
TFs are dysregulated in both AD and PD. In addition to 
this, we identified 12 SNPs that were shared between 
the 29 PD miRNAs associated SNPs and 27 AD 
miRNAs associated SNPs. This number of shared SNPs 
is highly significant, which suggests that there are 
potential risk factors that underlie both diseases. 
 
Several studies have applied WGCNA in ND studies for 
gene expression and proteomics analysis. For example, 
Seyfried and colleagues studied proteomic data of cortical 
tissue of asymptomatic and symptomatic AD [47]. They 
found that there was a modest overlap between networks 
at RNA and protein level. If a larger dataset becomes 
available, expanding our methods to proteomic data could 
give further understanding into the mechanisms of  AD 
and PD and enable the investigation into the link between 
genomics and proteomics. Chatterjee et al. [17] have 
performed network analysis of PD brain tissue, however 
they only performed WGCNA on DEGs found in the  
data, which built very limited networks that removed 
potentially important gene interactions and disease 
regulators and introduced a bias of modules and hubs 
towards these DEGs. In addition, they used tissue from 
multiple brain regions which would all be affected 
differently by the disease [48]. 
 
A limitation of this study is that, although it has been 
shown that AD blood DEGs are more likely to be 
DEGs in the brain [27], our results suggest this is not 
the case for PD. Because of this, our results may not 
reflect major changes that take place in the brain. 
However, our network analysis approach emphasizes 
the interactions of genes which univariate  methods  
like differential expression does not. Similarly to AD, 
there is disruption that happens in the blood brain 
barrier (BBB) of PD patients [49]. Hence, it is likely 
that changes that take place in the brain could be 
reflected in the blood and vice versa.  Additionally,  a 
lot of the biological processes and genes we found in 
our PD network has been implicated in the PD brain 
previously [11]. Tau and Aβ are hallmarks of both AD 
and PD in the brain and have potential as blood 
biomarkers in both diseases [50, 51], suggesting that 
changes in the brain are  reflected  in  blood. 
Leukocytes have been shown to impact progression of 
neurodegenerative diseases. An interaction between 
brain and systemic inflammation has  been  implicated 
in PD progression by an  association  between 
leukocyte apoptosis and central dopamine neuron loss 
[55]. Increased mitochondrial respiratory activity in 
leukocytes has been shown in PD patients, potentially 
impacting progression of neurodegeneration [56] and 
elevated leukocytes in cerebrospinal fluid are 
significantly associated with shorter survival  of 
patients [57]. Peripheral leukocytes have  been 
discussed as potential biomarkers for AD previously 
[52], and gene expression changes in leukocytes have 
been shown to be closely associated with AD 
progression [53]. In AD animal models circulating 
leukocytes have been shown to cross a dysfunctional 
blood brain barrier and impact brain integrity [54]. 
 
Recently limbic-predominant age-related TDP-43 
encephalopathy (LATE) has been reported to be under- 
recognized and often misdiagnosed as AD as they share 
common pathogenetic mechanisms and present 
similarly in patients [58]. There is the potential that 
patients in our AD cohort may have been misdiagnosed 
and actually have LATE, however as LATE is seen with 
increasing frequency over the age of 85, and less than 
6% of our AD samples were over the age of 85 this 
likely had little effect on our results. 
 
The greatest risk factor for both AD and PD is age. 
Adjusting AD data by age before WGCNA ensured any 
changes we found were reflective of disease state. The 
PD data, however, did not include samples’ age 
information when we downloaded, thus the effect of age 
could not be removed technically. As a result of this, the 
PD results may have been biased towards changes as a 
result of aging if there was a significant difference in 
age between PD and HC cohorts. However, the samples 
were age matched in the original design which should 
reduce such biases [59]. 
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From the PD dataset we removed patient samples with 
known PD mutations. Although the biological pathways 
underlying familial and sporadic forms of PD are likely 
to be shared, known PD mutations may impact 
pathways to disease or regulators of disease [60]. 
Removal of samples with known PD mutations 
prevented these mutations from having an impact on 
results, however had little impact on sample size due to 
the low number of samples with mutations. AD samples 
were not screened for known mutations, which could 
have had an impact on our results. For example, nearly 
19% of the familial late onset AD population carry 2 
APOE ε4 alleles which only occurs in about 1% of 
normal Caucasian controls [61]. This and other known 
mutations may impact the progression and regulators of 
AD, and knowing which samples had these mutations 
could have improved our findings. 
 
In conclusion, our network analysis is the largest study 
using AD and PD blood data to date. We highlight the 
non-preserved module in PD associated with insulin 
resistance, and the hub HDAC6 identified in this 
module. Our results reveal that a large proportion of 
disease miRNA associated SNPs are shared between PD 
and AD, suggesting similarities in genetic risk factors 
between the diseases. The hub genes that we have 
identified have the possibility to be further investigated 
as potential biomarkers for disease. These insights 
suggest several new areas for mechanistic studies in PD 
and AD research fields. 
 
MATERIALS AND METHODS 
 
Data preparation for PD and AD blood datasets 
 
The publicly available peripheral venous whole blood 
dataset comprising 205 PD and 233 control samples was 
downloaded from the GEO (Gene Expression Omnibus) 
database (http://www.ncbi.nlm.nih.gov/geo/) with 
accession identifier GSE99039. This dataset is the 
largest of its type and has a sample size enough to run 
WGCNA and reliably find hub genes [62]. Samples 
with known PD mutation genes (Parkin, DJ-1 and 
PINK1, ATP13A2, LRRK2, SNCA) were removed to 
reduce biases introduced by these genes (see 
discussion), and outlier samples were detected and 
removed based on box and density plots of probe 
intensities. This removed a total of one PD and three 
HC samples, leaving 204 PD and 230 HC samples. Data 
was then Robust Multiarray Average (RMA) 
normalized using the affy R package [63]. Samples 
missing gender information (35 samples) were assigned 
sex by using the massiR R package [64] which uses the 
information from microarray probes that  represent 
genes in Y chromosome to perform k-medoids 
clustering to classify the samples into male and female 
groups. We selected a probe-variation threshold of 4 by 
inspecting a probe-variation plot (Supplementary Figure 
1) to select the Y chromosome probes to be used in the 
sex classification process. 
 
The ComBat function in the sva R package [65] was 
used to control the effect of gender and running batch of 
the samples. After this, control probes and those without 
Entrez gene annotation were removed. For any genes 
that mapped to multiple probes, the probe with the 
highest median absolute deviation (MAD) was kept. 
MAD was used as, similarly to inter-quartile range, the 
probe with the highest MAD has the greatest variability 
and so likely has more information [66]. Finally, the 
bottom 5% probes by average expression values across 
all samples were removed. 
 
For AD, the two independent peripheral venous whole 
blood datasets GSE63060 and GSE63061, from the 
AddNeuroMed Cohort [67], were used to construct the 
blood gene expression networks. As these two datasets 
were from the same cohort study and sample collection 
and analysis was carried out using the same 
methodologies, except using different biological 
samples and microarray platforms, they can be merged 
to produce a larger dataset that can improve the power 
of our study. The two normalized datasets (generated by 
different Illumina platforms) were merged using the 
inSilicoMerging R package [68], which removes the 
batch effects between these two, as we have done 
previously [27]. 
 
Patients of Western European and Caucasian ethnicity 
were extracted from the merged dataset leaving a total 
of 245 AD, 142 MCI and 182 HC to reduce any 
potential genetic impact that ethnicity may have on  
AD. The effect of the age and gender were controlled 
for using the ComBat function in the sva R package 
[65]. As with the PD data, control probes and those 
without Entrez gene annotation were removed and for 
any genes that mapped to multiple probes, the probe 
with the highest MAD was kept. Finally, the bottom 
5% probes by average expression values across  
samples were removed. Information on number of 
samples, gender and age of samples is shown in 
Supplementary Table 1. 
 
PD blood and brain DEG overlap 
 
To see if there was a significant overlap between PD 
gene expression in blood and brain as has been shown 
previously in AD [27], our data was compared to DEGs 
previously identified in PD substantia nigra [11]. Using 
the normalized and filtered PD data, DEGs were 
identified by applying limma with gender and running 
batch adjusted. Slightly stringent nominal Pvalue <0.01 
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was used for significance as only one DEG could pass 
multiple testing (FDR corrected Pvalue <0.05). 
 
Gene co-expression network construction 
 
The R package WGCNA [15] was applied to perform 
gene co-expression network analysis as follows: A 
matrix of pairwise correlations between all pairs of 
genes across each sample group (e.g. case and control 
groups separately), was created and each raised to a 
soft-thresholding power to achieve a scale-free topology 
R2 of 0.85. From this, a topological overlap matrix 
(TOM) was calculated, which takes correlation between 
genes expression as well as connections the genes share 
into consideration. This TOM was then converted to 
topological overlap dissimilarities to be used with 
hierarchical clustering. Then, a dynamic tree-cutting 
algorithm was used to determine initial module 
assignments of genes (cutreeHybrid, using default 
parameters except deepSplit of 3, minModuleSize of 10 
and mergeCutHeight of 0.05) [69]. An additional k- 
means clustering step was applied to improve the results 
of the hierarchical clustering in WGCNA as proposed 
by Botía et al [70] which has been reported to be able to 
reduce the number of misplaced genes and improve the 
enrichment of GO pathway terms. All analysis was 
conducted in R3.5.2 [71]. 
 
Calculation of module preservation 
 
In order to identify modules that are not preserved 
between conditions within datasets, we applied NetRep 
(v1.2.1) [18] which uses a permutation test procedure on 
seven module preservation statistics. We permuted 10,000 
times. The “alternative” parameter is set to “less” to test 
whether each module preservation statistic is smaller than 
expected by chance in order to identify these non- 
preserved modules which are extremely different in the 
two networks. If all seven module preservation statistics 
had a Pvalue < 0.05 then that module was significantly 
non-preserved between conditions. 
 
Pathway enrichment analysis 
 
To identify the biological pathways that the modules 
represent we performed GO and KEGG pathway 
enrichment analysis (KEGG 2019) using the Enrichr 
web tool [19, 20]. Pathways and GO terms with a 
Pvalue < 0.05 were considered significant. 
 
Hub gene identification 
 
Generally, detecting hub genes in co-expression 
networks has been done using MM, which is the 
correlation of a gene to its eigengene (the first principle 
component calculated using the expression data of 
genes in each module) [72]. BC of a gene is the number 
of shortest paths connecting all gene pairs that pass 
through that gene [73], and genes with high BC were 
considered as "high traffic". 
 
Here we have expanded hub detection to include multiple 
other hub detection methods frequently used in network 
analysis. In addition to MM and BC, we used closeness 
centrality [74], Kleinberg's hub centrality score [75] and 
the PageRank algorithm [76] which would reduce the 
chance of missing any important hub genes that regulate 
the network that may be missed by applying individual 
methods. Genes with high closeness centrality scores have 
the shortest path to all other genes in the module and are 
placed to influence the entire network quickly [74]. 
PageRank emphasizes nodes that are connected to other 
nodes with high Pagerank scores [76]. Kleinberg's hub 
centrality score [75] is similar to the PageRank algorithm, 
however, the small differences between the two widens  
the net for identifying important hubs. 
 
A novel hub detection permutation test was developed 
to obtain Pvalues for each hub detection store and 
determine if they are statistically significant. Briefly,  
the gene ID labels on the adjacency matrix were 
randomly re-labelled and hub score recalculated 1000 
times to obtain a statistical distribution. The Pvalue was 
calculated by dividing the number of recalculated 
permutation hub scores that are higher than the  
observed hub score in the original network by the 
number of permutations. Genes were considered 
significant hubs if any hub scores had a Pvalue < 0.01. 
This was performed for all modules not preserved 
between PD and HCs in the PD dataset, and the 
modules not preserved between any of the AD, MCI  
and HCs networks in the AD dataset. BC, closeness 
centrality, PageRank and Kleinberg's hub centrality 
scores were calculated using the igraph R package with 
default settings without normalization [77]. The R code 
used for the novel hub detection test is available at 
http://dx.doi.org/10.5281/zenodo.3686007. 
 
Identifying transcription factors 
 
To identify TFs that potentially regulate each module, 
we used ENCODE and ChEA Consensus TFs from 
ChIP-X found using the Enrichr web tool [19, 20]. TFs 
with a Pvalue < 0.01 were considered significant. If a 
TF was found significant in both ENCODE and ChEA 
then the lower Pvalue was assigned to the TF. 
 
SNP and microRNA analysis of significant WGCNA 
modules 
 
A two-tailed Fisher’s exact test was used to test our 
hypothesis that non-preserved modules were more 
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likely to contain GWAS identified genes than preserved 
modules. The risk loci for PD and AD were from recent 
GWAS, between which only one GWAS gene was 
shared (KAT8) [24, 78]. 
 
We gained further insight into SNPs associated with 
non-preserved modules, using a similar methodology to 
Chatterjee et al. [17]. The SCAN database [25] was 
used to find all SNPs that have been shown to predict 
the expression of each gene within non-preserved 
modules. For each non-preserved module, only SNPs 
that predicted gene expression with Pvalues < 1.0e-4 
and frequency > 0.10 within the CEU human samples of 
European descent were selected. 
 
Previous studies have revealed that  differential  
expression of miRNAs were associated with PD [79] and 
AD [80]. In addition, SNPs have been identified as 
disease prognostic markers by association to miRNAs 
[81]. SNPs we found to be associated with genes  from 
the PD related modules were used to search the MirSNP 
[26] database in order to find which SNPs were 
associated with the 83 experimentally confirmed PD 
related miRNAs in the HMDD v3.0 database [82]. The 
same process was done for genes within the AD related 
modules and the 57 experimentally confirmed AD related 
miRNAs in the HMDD v3.0 database. The MirSNP 
database identified the SNPs that are present at the 3' 
untranslated region of miRNA target sites, and so 
narrowed down the selection of SNPs to those that likely 
effect known miRNAs associated with the disease. 
 
Comparison of PD and AD results 
 
The processes associated with non-preserved modules 
in AD and PD were compared to see if any processes 
were similar between diseases. Hub genes and TFs 
identified in non-preserved modules were also 
compared between AD and PD to see if any were 
shared. In addition, we test our hypothesis that AD and 
PD share SNPs we identified in non-preserved modules 
associated with disease related miRNAs in AD and PD 
respectively. 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figures 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. The probe variation plot used to determine which genes to use in massiR R package [53]. A threshold 
of 4 was selected as it encompassed the genes with the highest variation and ignores genes with low variation that may be useful in 
classifying samples. 
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Supplementary Figure 2. (A) The distribution of betweenness scores for each gene in the darkseagreen4 module. Many genes have a 
betweenness score of 0 indicating they do not act as hubs in regard to betweenness in this module. After the hub permutation test, one gene 
was found to be significant (GINS2, Pvalue = 0.005). (B) The distribution of betweenness scores for GINS2 over the 1000 iterations of the hub 
permutation test. The betweenness score of GINS2 in the original darkseagreen4 module network is highlighted. 
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Supplementary Tables 
 
Supplementary Table 1. Information on number of samples, sex and age of samples in datasets. 
 
GEO Dataset  No. sample Sex (male/female) Mean Age (±SD) 
GSE99039 PD 204 97/107 NA 
 HC 230 150/80 NA 
 All 434 247/187 NA 
GSE63060 + 
GSE63061 
AD 245 166/79 76.5 (± 6.6) 
MCI 142 79/66 74.9(± 6.3) 
 HC 182 110/72 73.6 (± 6.3) 
 All 569 352/217 75.2 (±6.5) 
 
 
Please browse Full Text version to see the data of Supplementary Table 2. 
 
Supplementary Table 2. Excel table of differentially expressed genes found in the PD dataset. 
 
 
Supplementary Table 3. Excel table of significant hubs found in non-preserved modules between PD and healthy 
controls. 
 
Module Gene 
Hub detection 
  method  
Score P-value 
PD modules not preserved in HC 
 GINS2 Betweenness 3826 0.005 
 
Darkseagreen4 
 
S1PR5 
Kleinberg’s 
centrality; 
PageRank; MM 
 
0.30751; 0.02637; 0.90234 
0.006; 0.006; 
0.007 
 AGBL2 Closeness 10.00256 0.007 
 NKG7 PageRank 0.02512 0.007 
  
SNRNP70 
PageRank; 
Kleinberg’s 
centrality 
 
0.02359; 0.27933 
 
0.003; 0.007 
Navajowhite2 POPDC2 Closeness 18.03573 0.008 
 
CHKB 
Kleinberg’s 
centrality 
0.28034 0.009 
 MIR142 MM 0.85297 0.009 
  
TYSND1 
PageRank; MM; 
Kleinberg’s 
centrality 
 
0.00978; 0.84787; 0.17499 
0.002; 0.002; 
0.008 
 C17orf97 Closeness 4.4882 0.002 
  
HDAC6 
Kleinberg’s 
centrality; MM; 
PageRank 
 
0.17867; 0.83636; 0.00958 
0.003; 0.006; 
0.007 
Salmon 
   
FAM114A1 Betweenness 12901 0.004 
 
ZNF804A 
Betweenness; 
Closeness 
12956; 4.27567 0.005; 0.007 
 ABCD1 PageRank; MM 0.00904; 0.83955 0.006; 0.006 
 ZNF526 PageRank 0.00908 0.006 
 TMEM147-AS1 Betweenness 12566 0.008 
 RENBP PageRank 0.00823 0.009 
HC modules not preserved in PD 
Purple FAM110C Closeness; 0.72585; 33683 0.000; 0.002 
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 Betweenness   
TXLNGY Betweenness 40661 0 
 
PAK4 
Kleinberg’s 
centrality; 
Pagerank; MM 
 
0.12262; 0.00467; 0.83401 
0.001; 0.002; 
0.003 
 
GIGYF1 
Kleinberg’s 
centrality; 
PageRank; MM 
 
0.12332; 0.00473; 0.85428 
0.002; 0.002; 
0.002 
 
WDTC1 
Kleinberg’s 
centrality; MM; 
PageRank 
 
0.11337; 0.82836; 0.00441 
0.002; 0.004; 
0.008 
NEB 
Closeness; 
Betweenness 
0.70015; 21395 0.003; 0.004 
SH3BGR 
Closeness; 
Betweenness 
0.63727; 19636 0.004; 0.005 
FCGBP Betweenness 16988 0.005 
 
INO80B 
PageRank; 
Kleinberg’s 
centrality; MM 
 
0.00417; 0.10391; 0.82766 
0.005; 0.007; 
0.007 
ZNF582-AS1 
Closeness; 
Betweenness 
0.59408; 0.06978 0.006; 0.008 
PLA2G4C Betweenness 20491 0.007 
TBC1D25 PageRank; MM 0.00401; 0.81547 0.007; 0.007 
 
MFSD12 
Kleinberg’s 
centrality; 
PageRank; MM 
 
0.10808; 0.00411; 0.80996 
0.007; 0.009; 
0.009 
MCM2 Closeness 0.57973 0.008 
SPATA6 Closeness 0.65087 0.009 
RPS6KA4 MM 0.80597 0.009 
FIZ1 MM 0.81009 0.009 
 
 
Please browse Full Text version to see the data of Supplementary Table 4. 
 
Supplementary Table 4. Excel table of significant hubs found in non-preserved modules between AD, MCI and 
healthy controls. 
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Supplementary Table 5. Excel file containing the significant TFs (Pvalue < 0.01) associated with each non- 
preserved module between PD and healthy control networks found using Enrichr (ENCODE and ChEA Consensus 
TFs from ChIP-X). 
 
Module colour Significant TFs P-value Gene overlap 
PD modules not preserved in HC 
Darkseagreen4 
FOXM1 4.004E-08 9/95 
E2F4 8.131E-08 21/710 
Navajowhite2 RUNX1 0.008305 18/1294 
Salmon FOXM1 0.006578 6/95 
HC modules not preserved in PD 
 SIX5 0.0001626 55/1094 
 ZBTB7A 0.0002814 94/2184 
Purple 
SRF 0.0008434 20/299 
CREB1 0.001402 64/1444 
 NFYB 0.004818 138/3715 
 PBX3 0.007364 54/1269 
 
 
Supplementary Table 6. Excel file containing the significant TFs (Pvalue < 0.01) associated with each non-preserved 
module between AD, MCI and healthy control networks found using Enrichr (ENCODE and ChEA Consensus TFs from 
ChIP-X). 
 
Module colour Significant TFs P-value Gene overlap 
AD modules not preserved in HC and MCI 
Blue 
SUZ12 3.36E-10 150/1684 
EZH2 0.0004579 26/237 
MCI modules not preserved in AD and HC 
Sienna3 SUZ12 8.24E-10 115/1684 
HC modules not preserved in AD and MCI 
Darkolivegreen 
SUZ12 0.00392 68/1684 
REST 0.009205 20/383 
 IRF3 0.000002884 24/663 
 SP2 0.000006359 30/994 
 NFYB 0.0000105 74/3715 
 GABPA 0.00001689 48/2082 
 BRCA1 0.0003388 61/3218 
 CTCF 0.0003775 39/1790 
Darkorange2 NFYA 0.0004409 46/2250 
 PBX3 0.0005193 30/1269 
 SIX5 0.00115 26/1094 
 SMC3 0.003293 26/1181 
 NR2C2 0.004466 11/350 
 FOS 0.006121 16/637 
 CREB1 0.007005 29/1444 
Skyblue RCOR1 0.002542 15/702 
 BCLAF1 0.006338 16/851 
HC modules not preserved in MCI 
Red 
SUZ12 1.21E-09 107/1684 
EZH2 0.0001041 21/237 
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Supplementary Table 7. Excel file containing the SNPs associated with PD SNPs in bold are shared between PD and 
AD. 
 
Chromosome SNPs 
Associated PD related 
miRNAs 
Modules with SNP associated gene Genes 
1 rs12140193 hsa-miR-495 PD darkseagreen4 METTL13 
 rs1138729 hsa-miR-495 PD salmon RRM2 
 rs12603 hsa-miR-543 HC purple EPB41L5 
2 rs2058703 hsa-miR-1283 HC purple; PD salmon BCL11A 
 rs4852735 hsa-miR-4271 PD navajowhite2 TEX261 
 rs707718 hsa-miR-543 HC purple CYP26B1 
3 
rs1135750 hsa-miR-147a PD navajowhite2 IQCB1 
rs11551405 hsa-miR-203 HC purple DCP1A 
4 rs3805317 hsa-miR-203 HC purple CLGN 
5 rs2561659 hsa-miR-543 HC purple AHRR 
 
6 
rs12528857 hsa-miR-203 
HC purple; PD darkseagreen4; PD salmon; PD 
navajowhite2 
TDRD6 
 rs1966 hsa-miR-543 HC purple; PD darkseagreen4 PSORS1C1 
7 rs1044718 hsa-miR-147a HC purple; PD darkseagreen4; PD salmon PARP12 
8 rs2929969 hsa-miR-133b; hsa-miR-203 PD darkseagreen4 WISP1 
9 
rs7047770 hsa-miR-133b HC purple; PD navajowhite2 C9orf139 
rs818055 hsa-miR-147a HC purple; PD navajowhite2 LAMC3 
10 rs1042192 hsa-miR-376b HC purple CYP2C18 
 rs10832733 hsa-miR-543 HC purple PIK3C2A 
11 
rs2512676 hsa-miR-147a PD darkseagreen4; PD salmon DLG2 
rs7126647 hsa-miR-543 PD navajowhite2 MRGPRX2 
 rs9444 hsa-miR-495 HC purple RNF169 
14 rs1054195 hsa-miR-543 PD navajowhite2 CLMN 
16 rs1568391 hsa-miR-495 PD darkseagreen4 IRF8 
17 rs3744711 hsa-miR-203 HC purple; PD salmon DHX33 
18 
rs1790974 hsa-miR-203 HC purple DOK6 
rs3745067 hsa-miR-4271 HC purple; PD darkseagreen4; PD salmon ONECUT2 
19 rs36621 hsa-miR-376b PD navajowhite2 TSEN34 
20 rs1060347 hsa-miR-134 HC purple PCMTD2 
22 rs712979 hsa-miR-203 HC purple C22orf39 
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Supplementary Table 8. Excel file containing the SNPs associated with AD SNPs in bold are shared between AD 
and PD. 
 
Chromosome SNPs 
Associated PD related 
miRNAs 
Modules with SNP associated gene Genes 
1 rs6660019 hsa-miR-433 AD blue; HC darkolivegreen; MCI sienna3 SASS6 
 rs12603 hsa-miR-543 HC darkorange2 EPB41L5 
2 
rs707718 hsa-miR-543 
AD blue; HC darkolivegreen; HC red; MCI 
sienna3 
CYP26B1 
 rs1135750 hsa-miR-147a HC skyblue IQCB1 
3 
rs11551405 hsa-miR-203 AD blue; HC darkorange2; HC red DCP1A 
rs340833 hsa-miR-433 HC skyblue IL5RA 
 rs6792607 hsa-miR-153 HC skyblue EIF5A2 
4 
rs3805317 hsa-miR-203 AD blue; HC red; MCI sienna3 CLGN 
rs8336 hsa-miR-203 AD blue SMARCAD1 
 rs10864 hsa-miR-433 AD blue; HC red; MCI sienna3 BCKDHB 
 
6 
rs12528857 hsa-miR-203 
AD blue; HC darkorange2; HC red; MCI 
sienna3 
TDRD6 
 rs1966 hsa-miR-543 AD blue; HC red; MCI sienna3 PSORS1C1 
 rs4709266 hsa-miR-433 AD blue; HC red; MCI sienna3 TAGAP 
7 rs1044718 hsa-miR-147a HC red PARP12 
 rs1042992 hsa-miR-495 HC darkorange2 BNIP3L 
8 rs2929969 hsa-miR-133b; hsa-miR-203 AD blue WISP1 
 rs732338 hsa-miR-134 AD blue; HC red; MCI sienna3 LZTS1 
10 rs7071789 hsa-miR-495 HC darkolivegreen TRUB1 
11 rs10832733 hsa-miR-543 HC darkorange2 PIK3C2A 
14 rs1054195 hsa-miR-543 AD blue; MCI sienna3 CLMN 
16 rs7294 hsa-miR-147a HC darkolivegreen VKORC1 
17 rs3744711 hsa-miR-203 HC darkorange2; HC skyblue DHX33 
18 
rs1046699 hsa-miR-433 AD blue; HC red; MCI sienna3 C18orf54 
rs608823 hsa-miR-433 AD blue; HC red; MCI sienna3 ONECUT2 
21 rs243609 hsa-miR-543 AD blue; HC red; MCI sienna3 C21orf91 
22 
rs137124 hsa-miR-134 AD blue CYB5R3 
rs17032 hsa-miR-495 HC darkolivegreen SUN2 
 
